Monday, February 9, 2026 at 5:57 AM
Innovent Biologics has formed a partnership with Eli Lilly to develop treatments for cancer and immune system diseases, with potential milestone payments reaching up to $8.5 billion.
Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
The pharma major said it faces the largest drug-patent expiry headwind in its history this year.
Data sourced from public RSS feeds and News APIs.
